Home - Products - Apoptosis - TNF - 4-Methoxysalicylaldehyde

4-Methoxysalicylaldehyde

CAS No. 673-22-3

4-Methoxysalicylaldehyde( —— )

Catalog No. M18979 CAS No. 673-22-3

4-Methoxysalicylaldehyde, a naturally occurring product, has a range of industrial applications in the preparation of organic compounds, drugs and therapeutic agents.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    4-Methoxysalicylaldehyde
  • Note
    Research use only, not for human use.
  • Brief Description
    4-Methoxysalicylaldehyde, a naturally occurring product, has a range of industrial applications in the preparation of organic compounds, drugs and therapeutic agents.
  • Description
    4-Methoxysalicylaldehyde, a naturally occurring product, has a range of industrial applications in the preparation of organic compounds, drugs and therapeutic agents.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    673-22-3
  • Formula Weight
    152.14
  • Molecular Formula
    C8H8O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 50 mg/mL 328.62 mM H2O : 2 mg/mL 13.14 mM
  • SMILES
    COC1=CC(=C(C=C1)C=O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Bioymifi

    Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis

  • Brentuximab

    Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

  • Dalbergin

    Dalbergin exhibits similar bone conserving effect against bone-loss as estradiol treatment, it as a therapeutic candidate against postmenopausal osteoporosis.